Physician profile
Maher Ajam
NPI 1548265135
$2,564.07
in general payments reported to CMS, 2019-2025
23 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $196 · 2021: $193 · 2022: $524 · 2023: $372 · 2024: $515 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $671.70 | 2019-2025 | Farxiga |
| Amgen INC. | $378.19 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Vifor Pharma, INC. | $250.04 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $200.10 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $177.05 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.35 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $128.44 | 2022-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $89.77 | 2022-2025 | Tarpeyo |
| Pfizer INC. | $87.11 | 2020 | |
| Travere Therapeutics, INC. | $66.83 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $58.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.09 | 2021-2025 | |
| Novo Nordisk INC | $35.05 | 2023-2025 | Ozempic |
| Scpharmaceuticals INC. | $32.40 | 2025 | |
| Ardelyx, INC. | $32.37 | 2023-2024 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.06 | 2020-2021 | |
| Lilly USA, LLC | $28.03 | 2024 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.35 | 2025 | |
| Alexion Pharmaceuticals, INC. | $23.93 | 2019 | |
| Akebia Therapeutics INC | $18.75 | 2022 | |
| Opko Pharmaceuticals, LLC | $17.27 | 2019 | |
| Daiichi Sankyo INC. | $16.39 | 2022 | |
| Horizon Therapeutics Plc | $13.29 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Ajam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.